Entorhinal Cholecystokinin in Alzheimer’s Disease: Its Earliest Vulnerability and Rescue Effects Across Different Disease Stages in a Mouse Model
Open Access
- 14 February 2026
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline. The entorhinal cortex (Ent) is among the earliest affected regions, and its neuropeptide cholecystokinin (CCK) supports neocortical-associated memory. Although our previous work demonstrated that CCK treatment rescues cognition and neuroplasticity in aged AD mice, the correlations among CCK expression, synaptic function, and cognitive decline with aging remain poorly understood. Using 3xTg-AD mice (2–18 months), we performed stereological, histological, and molecular analyses to evaluate brain atrophy, neuronal loss, glial responses, and gene expression. Cognitive function was assessed using the novel object recognition test (NOR), motor learning was evaluated using the rotarod test, and synaptic integrity was measured via electrophysiological recordings. We also investigated the therapeutic potential of CCK-B receptor (CCK-BR) agonists on learning and memory and neuroplasticity across disease stages of AD. In 3xTg-AD mice, the Ent exhibits significant atrophy and excitatory neuronal loss as early as 7 months of age, confirming its role as one of the earliest and most severely affected regions in AD. CCK was downregulated earlier than other synaptic genes in the Ent and other brain regions. Cholecystokinin tetrapeptide (CCK-4) treatment rescued deficits in synaptic plasticity, cognition, and motor learning in 3xTg-AD mice across multiple disease stages. Long-term administration of HT-267, a CCK-BR agonist with a prolonged half-life, in young 3xTg-AD mice delayed cognitive decline, enhanced synaptic scaffolding, and restored long-term potentiation in both the cortex and hippocampus (HPC). Our findings identify CCK downregulation as an early biomarker in AD and demonstrate the therapeutic effects of CCK-BR agonists in mitigating cognitive and synaptic deficits from mild to severe disease stages. The ability of long-term CCK-4 analogue treatment to decelerate AD progression indicates its promise as an early intervention strategy. Graphical AbstractKeywords
All Related Versions
Funding Information
- Hong Kong Research Grants Council, General Research Fund (CityUHK 11103922, CityUHK 11104923, CityUHK 11104524)
- Hong Kong research grants council, collaborative research fund (C1043-21G, C1002-24W)
- Hong Kong Research Grants Council, Senior Research Fellow Scheme (SRFS2324-1S02)
- Hong Kong Health Bureau, Health and Medical Research Fund (09203656)
- Innovation Technology Commission of the Hong Kong SAR, China: Health@InnoHK program
- Wong Chun Hong Endowed Chair Professorship
- Charlie Lee Charitable Foundation
- Fong Shu Fook Tong Foundation
This publication has 71 references indexed in Scilit:
- Neuropathology of Alzheimer's DiseaseNeurotherapeutics, 2022
- The Role of Synapsins in Neurological DisordersNeuroscience Bulletin, 2017
- Cholecystokinin: A multi‐functional molecular switch of neuronal circuitsDevelopmental Neurobiology, 2010
- Selective Preservation and Degeneration Within the Prefrontal Cortex in Aging and Alzheimer DiseaseArchives of Neurology, 2001
- Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methodsJournal of Neuroscience Research, 2001
- Clinical features of Alzheimer's diseaseEuropean Archives of Psychiatry and Clinical Neuroscience, 1999
- Evolution of neuronal changes in the course of Alzheimer’s disease1998
- Microglia: a sensor for pathological events in the CNSTrends in Neurosciences, 1996
- Unbiased stereological estimation of the number of neurons in the human hippocampusJournal of Comparative Neurology, 1990
- Neuropeptides in Alzheimer's disease, depression and schizophreniaJournal of the Neurological Sciences, 1981